<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77131">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763645</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-021-02</org_study_id>
    <nct_id>NCT01763645</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer</brief_title>
  <official_title>International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-021-02 is a double-blind randomized clinical trial comparing efficacy of BCD-021 (INN:
      bevacizumab) and paclitaxel + carboplatin to Avastin and paclitaxel + carboplatin in
      inoperable or advanced non-squamous NSCLC patients with pharmacokinetics substudy. The
      purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-021
      compared to Avastin. Also study includes pharmacokinetics assessment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>No</safety_issue>
    <description>primary outcome measure for efficacy evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve after the first test drug administration</measure>
    <time_frame>up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)</time_frame>
    <safety_issue>No</safety_issue>
    <description>primary outcome measure for pharmacokinetics (PK) substudy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response rate</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stabilization rate</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative number (%) of chemotherapy cycles, postponed due to adverse events (AE)</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>secondary outcome measure for safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuation rate due to AE</measure>
    <time_frame>Day 127</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>secondary outcome measure for safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and titer of anti-bevacizumab antibodies</measure>
    <time_frame>Day 1 (before the drug administration), Day 15, 64 and 127</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measure for immunogenicity assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for PK substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for PK substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>secondary outcome measure for PK substudy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE incidence and severity</measure>
    <time_frame>Up to Day 148</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>secondary outcome measure for safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs grade 3-4 incidence</measure>
    <time_frame>Up to Day 148</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>secondary outcome measure for safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimal serum bevacizumab concentration</measure>
    <time_frame>Day 22, Day 43, Day 64, Day 85, Day 106, Day 127</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measure for pharmacokinetics analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>BCD-021 (CISC BIOCAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avastin (F. Hoffmann-La Roche Ltd)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).</description>
    <arm_group_label>BCD-021 (CISC BIOCAD)</arm_group_label>
    <arm_group_label>Avastin (F. Hoffmann-La Roche Ltd)</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>BCD-021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)</description>
    <arm_group_label>BCD-021 (CISC BIOCAD)</arm_group_label>
    <arm_group_label>Avastin (F. Hoffmann-La Roche Ltd)</arm_group_label>
    <other_name>Taxacad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).</description>
    <arm_group_label>BCD-021 (CISC BIOCAD)</arm_group_label>
    <arm_group_label>Avastin (F. Hoffmann-La Roche Ltd)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent;

          -  Newly diagnosed histologically or cytologically confirmed NSCLC excluding squamous
             NSCLC (mixed cancer types should be classified according to the prevalent cell type);

          -  IIIb or IV stage of NSCLC (TNM classification version 6);

          -  Age ≥ 18 years and age ≤ 70 years (both inclusive);

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, (not
             declining within 2 weeks prior to the first dose of investigational product);

          -  Life expectancy - 12 weeks or more from the moment of randomization;

          -  Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed
             with CT slice thickness not more than 5 mm), as defined by modified Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria (specifically, no ascites,
             pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous
             lymphangitis of the lung as only lesion;

          -  Patients should be able to follow the Protocol procedures (according to
             Investigator's assessment);

          -  Patients must implement reliable contraceptive measures during all the study
             treatment, starting 4 weeks prior to the administration of the first dose of
             investigational product until 6 months after the last dose of investigational
             product. This requirement does not apply to participants who have undergone surgical
             sterilization, or patients who are postmenopausal (documented) for the past 2 years.
             Reliable contraceptive measures include two methods of contraception, including one
             barrier method

        Exclusion Criteria:

          -  Squamous NSCLC;

          -  Proven coagulopathy, clinically significant hemorrhage in the past including nasal
             hemorrhage;

          -  absolute neutrophil count &lt;1500/mm3;

          -  Platelets &lt;100 000/mm3;

          -  Hemoglobin &lt; 90 g/L;

          -  Creatinine level ≥1.5 mg/dL;

          -  Bilirubin level ≥1.5 × upper limit of normal (ULN);

          -  Aspartate-aminotransferase(AST) and alanine-aminotransferase (ALT) levels ≥2.5 × ULN
             (≥5 × ULN for patients with liver metastases);

          -  Alkaline phosphatase level ≥5 × ULN;

          -  Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day),
             nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment
             with these drugs  less than 1 month before entering the study;

          -  Uncontrolled hypertension comprising all cases of arterial hypertension when no
             decrease in blood pressure could be achieved despite treatment with a combination of
             3 antihypertensive drugs including one diuretic and non-medical correction methods
             (low salt diet, physical exercise);

          -  Previous anticancer therapy of metastatic NSCLC;

          -  Radiation or hormone therapy within 21 days prior to randomization;

          -  Major surgery 28 days before inclusion into the study;

          -  Previous antiangiogenic therapy;

          -  Hypersensitivity to taxanes, platinum agents, recombinant murine proteins, contrast
             agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine,
             ranitidine) or excipients of investigational products;

          -  NSCLC metastases in   central nervous system excluding metastases non-progressing
             without glucocorticosteroids within 4 weeks before inclusion into the trial;

          -  Cardiovascular system pathology (CHF stage III-IV according to New York Heart
             Association (NYHA) classification);

          -  Pregnancy or lactation;

          -  Conditions limiting patient's adherence to Protocol requirements (dementia,
             neurologic or psychiatric disorders, drug addiction, alcoholism and others);

          -  Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events
             (CTCAE) v.4.0;

          -  Simultaneous participation in other clinical trials, previous participation in other
             clinical trials within 30 days before entering into the trial, previous participation
             in the same trial;

          -  Any other concomitant cancer revealed within 5 years prior to screening, except
             curatively treated intraductal carcinoma in situ, curatively treated cervical
             carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;

          -  Acute or active chronic infections;

          -  Hepatitis C virus, hepatitis B virus, HIV, or syphilis infections;

          -  Obstacles in intravenous administration of study drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrey Biryulin, MD</last_name>
    <phone>+7 (812) 380-49-33</phone>
    <phone_ext>925</phone_ext>
    <email>biryulin@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Filon, MD</last_name>
    <phone>+7 (812) 380-49-33</phone>
    <phone_ext>916</phone_ext>
    <email>filonov@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brest Regional Clinical Dispensary</name>
      <address>
        <city>Brest</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grodno Regional Clinical Hospital</name>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCG Bangalore Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narayana Hrudayalaya Hospitals</name>
      <address>
        <city>Bangalore</city>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>M.S.Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk District Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State-financed Health Institution &quot;Chelyabinsk Region Clinical Oncology Dispansary&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Non-governmental Healthcare Institution &quot;Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Healthcare Facility &quot;Kursk Regional Oncology Dispensary&quot;</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Moscow Institute of Cancer Research named after P.A. Hertsen&quot; Ministry of Health of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institution of Russian Academy of Medical Sciences &quot;Russian Cancer Research Center named after N.N. Blokhin&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Health Institution of Moscow &quot;Moscow City Oncology Hospital #62 of Moscow Board of Health&quot;</name>
      <address>
        <city>Moscow Region</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Murmansk Regional Oncology Dispensary</name>
      <address>
        <city>Murmansk</city>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Region State Budgetary Healthcare Facility &quot;Clinical Diagnostics Center&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Healthcare Facility &quot;Nizhny Novgorod Regional Oncology Dispensary&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №1</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional State Health Institution &quot;Orlov Oncology Dispansary&quot;</name>
      <address>
        <city>Orel</city>
        <zip>302020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Health Institution &quot;Region Oncology Dispansary&quot;</name>
      <address>
        <city>Penza</city>
        <zip>440071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perm Region Oncology Dispensary</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal Government Budgetary Institution &quot;Rostov Institute of Cancer Research&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>314019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg City Clinical Oncology Center</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State-financed Health Institution &quot;Samara Region Clinical Oncology Dispansary&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Dispensary 2</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Medical University n.a. I. P. Pavlov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Research and Practice Center for Secondary Care in Oncology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>N.N.Petrov Oncology Research Center</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian scientific center of radiology and surgery technologies</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy named after S.M. Kirov</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State-financed Health Institution &quot;Stavropol Region Clinical Oncology Dispansary&quot;</name>
      <address>
        <city>Stavropol</city>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Volgograd District Oncology Dispensary №1</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Oncology Dispensary №3</name>
      <address>
        <city>Volgograd</city>
        <zip>404130</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Health Institution &quot;Voronezh Region Clinical Oncology Dispansary&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Antitumor Center</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Donetsk City Oncology Dispensary</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kharkiv Regional Clinical Oncology Center</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kryvyi Rih Oncology Dispensary</name>
      <address>
        <city>Kryvyi Rih</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lviv State Regional Cancer Diagnostic and Treatment Center</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospital № 2</name>
      <address>
        <city>Makiivka</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poltava Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zakarpatskyi Clinical Oncology Dispensary</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zaporizhia Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Zaporizhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.biocad.ru</url>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
